ACTU
ACTUATE THERAPEUTICS, INC.
NASDAQ · Healthcare · Biotechnology · US
$0.58
−3.45%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$0.67
From 52W high−92.34%
Volume723723.00
Market cap$14.03M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 19, 2026
Open
$0.67
From 52W high
−92.34%
Volume
723723.00
Market cap
$14.03M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.5x
P/E (TTM)
—
RSI (14)
40.5
MomentumView details →
1D Return
−3.45%
YTD Return
−90.20%
SummaryUpdated Jun 1, 2026
Actuate Therapeutics Inc (NASDAQ:ACTU) is a clinical-stage biopharmaceutical company founded in 2015 and based in Fort Worth, Texas. Originally incorporated as Apotheca Therapeutics, the company changed its name to Actuate Therapeutics in October 2015. The company went public in August 2024 and focuses on developing novel cancer therapies, with its lead product candidate being a glycogen synthase kinase-3 inhibitor for treating various forms of cancer including pancreatic, colorectal, and rare cancers.
Similar companies
Latest newsMore news →
No recent news for ACTU.